Skip to content

Price / sales at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
24.8×-26.8×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
18.1×+2.5×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.3×
Biogen logo
BiogenBIIB
2.7×+0.7×
Globus Medical logo
Globus MedicalGMED
3.8×-0.3×
Cytokinetics logo
CytokineticsCYTK
76.7×-171×

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Calculated from BioMarin Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's price / sales?
BioMarin Pharmaceuticals (BMRN) reported price / sales of 3.4× in Q1 2026.
How has BioMarin Pharmaceuticals's price / sales changed year-over-year?
BioMarin Pharmaceuticals's price / sales decreased by 26.7% year-over-year, from 4.6× to 3.4×.
What is the long-term trend for BioMarin Pharmaceuticals's price / sales?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's price / sales has grown at a -16.3% compound annual growth rate (CAGR), from 8.7× to 3.5×.
What does price / sales mean?
How many dollars investors pay for each dollar of the company's annual sales.
How do you interpret price / sales?
Useful when earnings are negative or volatile (e.g. early-stage or cyclical firms). Only comparable across companies with similar margins — a sales dollar is worth more at a high-margin business.
How does price / sales compare across companies?
Best compared within a margin cohort; a software P/S and a retailer P/S are not directly comparable.